NCT05127135View on ClinicalTrials.gov

Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 22, 2020

Primary Completion Date

January 24, 2023

Study Completion Date

December 24, 2023

Conditions
T-Acute Lymphoblastic LeukemiaT-cell Non-Hodgkin LymphomaT-cell Acute Lymphoblastic Lymphoma
Interventions
BIOLOGICAL

ThisCART7 cells

0.5-6 x 10\^6 CAR T cells per kg body weight

Trial Locations (2)

Unknown

RECRUITING

The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Hefei

RECRUITING

Fundamenta Therapeutice Co.,Ltd, Suzhou

Sponsors
All Listed Sponsors
collaborator

The First Affiliated Hospital of University of Science and Technology of China

OTHER

lead

Fundamenta Therapeutics, Ltd.

INDUSTRY

NCT05127135 - Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies | Biotech Hunter | Biotech Hunter